Plecanatide

At a glance

Overview

Trulance is used for two adult constipation diagnoses: chronic idiopathic constipation and irritable bowel syndrome with constipation. The first centers on persistent difficult or infrequent bowel movements without an identified secondary cause; IBS-C also includes a pattern of abdominal pain. Plecanatide does not treat mechanical obstruction and is not established as a general gut-healing or anti-inflammatory medicine. Its limited systemic absorption is relevant to pharmacology, but the clinically important effect is movement of fluid into the intestine, which can become excessive in susceptible patients.

Supporting sources [1] [2]

How it works

Plecanatide resembles the endogenous peptide uroguanylin and activates guanylate cyclase-C on intestinal epithelial cells. Increased cyclic GMP stimulates chloride and bicarbonate secretion, principally through CFTR, increasing luminal fluid and transit. Animal findings also link extracellular cyclic GMP to reduced pain-nerve activity. Clinical improvement in IBS-C is evaluated by patient symptoms and bowel outcomes rather than that laboratory mechanism alone.

Supporting sources [1] [2]

Two adult indications

U.S. labeling covers chronic idiopathic constipation and IBS-C in adults. Safety and effectiveness below age eighteen are not established. Eligibility is based on the constipation diagnosis, not simply a desire to improve digestion or bowel frequency.

Supporting sources [1]

Clinical trial outcomes

A phase 3 placebo-controlled trial in chronic idiopathic constipation assessed sustained complete spontaneous bowel-movement response. Plecanatide improved that endpoint, supporting a measurable bowel-function benefit rather than a claim that it corrects every underlying cause of constipation.

Supporting sources [2]

Diarrhea and dehydration

Diarrhea is the common adverse reaction and can be severe. The label includes a boxed warning for serious dehydration risk in pediatric patients. Minimal measurable drug in the circulation does not prevent dehydration caused by its local intestinal effect.

Supporting sources [1]

Pediatric and obstruction restrictions

Plecanatide is contraindicated below age six and in known or suspected mechanical gastrointestinal obstruction. The label advises avoiding use from six to under eighteen because pediatric safety and effectiveness have not been established.

Supporting sources [1]

Relationship to linaclotide

Both medicines activate intestinal GC-C, but they are different peptides with different product labels. In particular, current linaclotide pediatric approvals should not be transferred to plecanatide merely because the two drugs share a receptor target.

Supporting sources [1]